Short-term effects of Lumacaftor/Ivacaftor (Orkambi™) on exertional symptoms, exercise performance, and ventilatory responses in adults with cystic fibrosis

RATIONALE: Lumacaftor/ivacaftor (LUM/IVA) modestly improves lung function following 1 month of treatment but it is unknown if this translates into improvements in exercise endurance and exertional symptoms. METHODS: Adult CF participants completed a symptom-limited constant load cycling test with si...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Respir Res
Autors principals: Quon, Bradley S., Ramsook, Andrew H., Dhillon, Satvir S., Mitchell, Reid A., Boyle, Kyle G., Wilcox, Pearce G., Guenette, Jordan A.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Letter to the Editor
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7268353/
https://ncbi.nlm.nih.gov/pubmed/32487229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-020-01406-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars